An FDA approval in tenosynovial giant cell tumor, a breakthrough therapy designation in melanoma, and encouraging findings in trials in bladder cancer, lung cancer, and a cell-free DNA assay.
Publications
Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study
In a prospective cohort of women in France, researchers assessed melanoma risk in relation to menopausal hormone therapy (MHT) use.
Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review
In melanoma patients, the efficacy and safety of two treatment regimens were compared: BRAF inhibition plus MEK inhibition combination therapy vs BRAF inhibition monotherapy, via this meta-analysis.
Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti–PD-1 in patients with metastatic melanoma
Researchers sought to determine the incidence, patterns of disease progression, and outcomes of melanoma brain metastases (MBM) in patients treated with anti–PD-1 immunotherapy.